Zinzani P L, Martelli M, Tura S, Mandelli F
Istituto di Ematologia L. e A. Seràgnoli, Università di Bologna, Italy.
Haematologica. 1993 Jan-Feb;78(1):40-3.
Granulocyte colony stimulating factor (G-CSF) safely stimulates the production of neutrophils in normal people and neutropenic patients. Phase II studies have been completed that explored the role of G-CSF in either abrogating or accelerating recovery from chemotherapy-induced neutropenia.
Fourteen patients with resistant/relapsed high-grade non-Hodgkin's lymphoma were treated with a dexamethasone, cytarabine and cisplatin (DHAP) regimen, and with G-CSF between chemotherapeutic courses.
All patients showed a rise in neutrophil count; none was neutropenic when hospitalized for subsequent DHAP courses. Furthermore, the interval between cycles was decreased in 11 of the 14 patients. The overall response rate was 86%, with 4 patients obtaining complete remission.
Administration of G-CSF was associated with an acceleration of neutrophil recovery, indicating its potential to reduce the risk of infection and to maintain planned chemotherapy doses.
粒细胞集落刺激因子（G-CSF）可安全地刺激正常人和中性粒细胞减少患者的中性粒细胞生成。已完成的II期研究探讨了G-CSF在消除或加速化疗引起的中性粒细胞减少恢复中的作用。
14例难治性/复发性高级别非霍奇金淋巴瘤患者接受地塞米松、阿糖胞苷和顺铂（DHAP）方案治疗，并在化疗疗程之间使用G-CSF。
所有患者中性粒细胞计数均升高；在随后因DHAP疗程住院时，无一例患者出现中性粒细胞减少。此外，14例患者中有11例的周期间隔缩短。总缓解率为86%，4例患者获得完全缓解。
给予G-CSF与中性粒细胞恢复加速有关，表明其有降低感染风险和维持计划化疗剂量的潜力。
